Cargando…
Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia
SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a dangerous cancer of the blood. In recent years, a series of drugs was approved to specifically target misdirected processes in the cancerous cells. These so-called “small molecules” substantially improved therapeutic outcomes, but eventually leukemia...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526197/ https://www.ncbi.nlm.nih.gov/pubmed/37760544 http://dx.doi.org/10.3390/cancers15184573 |
_version_ | 1785110964457177088 |
---|---|
author | Lang, Tonio Johannes Lukas Damm, Frederik Bullinger, Lars Frick, Mareike |
author_facet | Lang, Tonio Johannes Lukas Damm, Frederik Bullinger, Lars Frick, Mareike |
author_sort | Lang, Tonio Johannes Lukas |
collection | PubMed |
description | SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a dangerous cancer of the blood. In recent years, a series of drugs was approved to specifically target misdirected processes in the cancerous cells. These so-called “small molecules” substantially improved therapeutic outcomes, but eventually leukemia returns in most patients. In this review, we summarize the current state of knowledge regarding the mechanisms that lead to failure of the most frequently used new therapies and introduce potential strategies to overcome the mechanisms associated with disease recurrence. ABSTRACT: In recent years, great progress has been made in the therapy of AML by targeting cellular processes associated with specific molecular features of the disease. Various small molecules inhibiting FLT3, IDH1/IDH2, and BCL2 have already gained approval from the respective authorities and are essential parts of personalized therapeutic regimens in modern therapy of AML. Unfortunately, primary and secondary resistance to these inhibitors is a frequent problem. Here, we comprehensively review the current state of knowledge regarding molecular processes involved in primary and secondary resistance to these agents, covering both genetic and nongenetic mechanisms. In addition, we introduce concepts and strategies for how these resistance mechanisms might be overcome. |
format | Online Article Text |
id | pubmed-10526197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105261972023-09-28 Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia Lang, Tonio Johannes Lukas Damm, Frederik Bullinger, Lars Frick, Mareike Cancers (Basel) Review SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a dangerous cancer of the blood. In recent years, a series of drugs was approved to specifically target misdirected processes in the cancerous cells. These so-called “small molecules” substantially improved therapeutic outcomes, but eventually leukemia returns in most patients. In this review, we summarize the current state of knowledge regarding the mechanisms that lead to failure of the most frequently used new therapies and introduce potential strategies to overcome the mechanisms associated with disease recurrence. ABSTRACT: In recent years, great progress has been made in the therapy of AML by targeting cellular processes associated with specific molecular features of the disease. Various small molecules inhibiting FLT3, IDH1/IDH2, and BCL2 have already gained approval from the respective authorities and are essential parts of personalized therapeutic regimens in modern therapy of AML. Unfortunately, primary and secondary resistance to these inhibitors is a frequent problem. Here, we comprehensively review the current state of knowledge regarding molecular processes involved in primary and secondary resistance to these agents, covering both genetic and nongenetic mechanisms. In addition, we introduce concepts and strategies for how these resistance mechanisms might be overcome. MDPI 2023-09-15 /pmc/articles/PMC10526197/ /pubmed/37760544 http://dx.doi.org/10.3390/cancers15184573 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lang, Tonio Johannes Lukas Damm, Frederik Bullinger, Lars Frick, Mareike Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia |
title | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia |
title_full | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia |
title_fullStr | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia |
title_full_unstemmed | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia |
title_short | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia |
title_sort | mechanisms of resistance to small molecules in acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526197/ https://www.ncbi.nlm.nih.gov/pubmed/37760544 http://dx.doi.org/10.3390/cancers15184573 |
work_keys_str_mv | AT langtoniojohanneslukas mechanismsofresistancetosmallmoleculesinacutemyeloidleukemia AT dammfrederik mechanismsofresistancetosmallmoleculesinacutemyeloidleukemia AT bullingerlars mechanismsofresistancetosmallmoleculesinacutemyeloidleukemia AT frickmareike mechanismsofresistancetosmallmoleculesinacutemyeloidleukemia |